Spots Global Cancer Trial Database for recurrent bladder carcinoma

Every month we try and update this database with for recurrent bladder carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer	NCT00118040	Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd...	Genistein Laboratory Biom... Pharmacological... Placebo Adminis... Therapeutic Con...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer	NCT02437370	Metastatic Urot... Recurrent Bladd... Recurrent Uroth... Regional Urothe... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Urethral Urothe...	Pembrolizumab Docetaxel Gemcitabine Hyd...	18 Years -	University of California, Davis
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer	NCT00118040	Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd...	Genistein Laboratory Biom... Pharmacological... Placebo Adminis... Therapeutic Con...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer	NCT02808143	Recurrent Bladd... Stage 0a Bladde... Stage 0is Bladd... Stage I Bladder...	BCG Solution Laboratory Biom... Pembrolizumab Pharmacological...	18 Years -	Northwestern University
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer	NCT01050504	Localized Renal... Malignant Solid... Metastatic Mali... Metastatic Mali... Metastatic Rena... Recurrent Bladd... Recurrent Prost... Recurrent Renal... Stage IV Bladde... Stage IV Bladde... Stage IV Prosta...	Cytology Specim... Laboratory Biom...	18 Years -	University of Washington
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations	NCT03047213	Locally Advance... Metastatic Tran... Metastatic Urot... Recurrent Bladd... Stage III Bladd... Stage IV Bladde...	Sapanisertib	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer	NCT02437370	Metastatic Urot... Recurrent Bladd... Recurrent Uroth... Regional Urothe... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Urethral Urothe...	Pembrolizumab Docetaxel Gemcitabine Hyd...	18 Years -	University of California, Davis
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery	NCT02169284	Bladder Carcino... Recurrent Bladd...	Erlotinib Hydro... Laboratory Biom... Pharmacological... Placebo Quality-of-Life... Therapeutic Con...	18 Years -	National Cancer Institute (NCI)
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy	NCT00072137	Bladder Adenoca... Bladder Squamou... Bladder Urothel... Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde...	Recombinant Fow... Recombinant Fow... Therapeutic Con... Pharmacological... Laboratory Biom...	-	National Cancer Institute (NCI)
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer	NCT02767921	Infiltrating Bl... Recurrent Bladd... Stage I Prostat... Stage I Renal C... Stage II Bladde... Stage II Renal ... Stage IIA Prost... Stage IIB Prost... Stage III Prost... Stage III Renal...	Cytology Specim... Laboratory Biom... Radical Cystect... Recombinant Eph... Therapeutic Con...	18 Years -	University of Southern California
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer	NCT03552796	Recurrent Bladd... Bladder Cancer ... Bladder Cancer ...	Pharmacokinetic... Recombinant Eph...	18 Years - 80 Years	University of Southern California
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer	NCT01938573	Recurrent Bladd... Stage II Bladde... Stage III Bladd... Stage IV Bladde...	Cisplatin Gemcitabine Hyd... Sirolimus Cystectomy	18 Years -	University of Washington
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer	NCT02437370	Metastatic Urot... Recurrent Bladd... Recurrent Uroth... Regional Urothe... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Urethral Urothe...	Pembrolizumab Docetaxel Gemcitabine Hyd...	18 Years -	University of California, Davis
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer	NCT03552796	Recurrent Bladd... Bladder Cancer ... Bladder Cancer ...	Pharmacokinetic... Recombinant Eph...	18 Years - 80 Years	University of Southern California
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	NCT03229278	Lymphoma Metastatic Mali... Metastatic Mela... Metastatic Rena... Recurrent Bladd... Recurrent Class... Recurrent Head ... Recurrent Lymph... Recurrent Malig... Recurrent Renal... Stage III Bladd... Stage III Lymph... Stage III Non-S... Stage III Renal... Stage III Skin ... Stage IIIA Non-... Stage IIIA Skin... Stage IIIB Non-... Stage IIIB Skin... Stage IIIC Skin... Stage IV Bladde... Stage IV Lympho... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Bladd... Stage IVB Bladd... Unresectable He... Unresectable So...	Enzyme Inhibito... Laboratory Biom... Nivolumab Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy	NCT00072137	Bladder Adenoca... Bladder Squamou... Bladder Urothel... Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde...	Recombinant Fow... Recombinant Fow... Therapeutic Con... Pharmacological... Laboratory Biom...	-	National Cancer Institute (NCI)
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer	NCT01938573	Recurrent Bladd... Stage II Bladde... Stage III Bladd... Stage IV Bladde...	Cisplatin Gemcitabine Hyd... Sirolimus Cystectomy	18 Years -	University of Washington
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer	NCT01050504	Localized Renal... Malignant Solid... Metastatic Mali... Metastatic Mali... Metastatic Rena... Recurrent Bladd... Recurrent Prost... Recurrent Renal... Stage IV Bladde... Stage IV Bladde... Stage IV Prosta...	Cytology Specim... Laboratory Biom...	18 Years -	University of Washington
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer	NCT01050504	Localized Renal... Malignant Solid... Metastatic Mali... Metastatic Mali... Metastatic Rena... Recurrent Bladd... Recurrent Prost... Recurrent Renal... Stage IV Bladde... Stage IV Bladde... Stage IV Prosta...	Cytology Specim... Laboratory Biom...	18 Years -	University of Washington
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations	NCT02646319	Advanced Malign... Cervical Squamo... Endometrial Car... Malignant Uteri... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Head ... Recurrent Malig... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Solid Neoplasm Stage III Bladd... Stage III Prost... Stage III Renal... Stage IIIA Brea... Stage IIIA Cerv... Stage IIIA Ovar... Stage IIIB Brea... Stage IIIB Cerv... Stage IIIB Ovar... Stage IIIC Brea... Stage IIIC Ovar... Stage IV Breast... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IVA Bladd... Stage IVA Cervi... Stage IVB Bladd... Stage IVB Cervi...	Laboratory Biom... Nanoparticle Al... Quality-of-Life...	18 Years -	Mayo Clinic
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations	NCT03047213	Locally Advance... Metastatic Tran... Metastatic Urot... Recurrent Bladd... Stage III Bladd... Stage IV Bladde...	Sapanisertib	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer	NCT02808143	Recurrent Bladd... Stage 0a Bladde... Stage 0is Bladd... Stage I Bladder...	BCG Solution Laboratory Biom... Pembrolizumab Pharmacological...	18 Years -	Northwestern University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: